Fagan Associates Inc. Trims Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Fagan Associates cut its stake in Bristol Myers Squibb (BMY) by 93.7% in Q4, selling 66,048 shares and leaving 4,452 shares valued at about $240,000.
• BMY reported Q earnings of $1.26 EPS (missing the $1.65 consensus) on $12.50 billion revenue, and set FY2026 guidance of 6.050–6.350 EPS versus analyst expectations around 6.28.
• The company announced a quarterly dividend of $0.63 per share (annualized $2.52) with an ex-dividend date of April 2, implying a yield near 4.3%.

Fagan Associates Inc. cut its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 93.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,452 shares of the biopharmaceutical company's stock after selling 66,048 shares during the period. Fagan Associates Inc.'s holdings in Bristol Myers Squibb were worth $240,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Simplicity Wealth LLC raised its position in Bristol Myers Squibb by 18.5% in the fourth quarter. Simplicity Wealth LLC now owns 9,164 shares of the biopharmaceutical company's stock valued at $494,000 after purchasing an additional 1,429 shares during the period. Joel Isaacson & Co. LLC grew its holdings in shares of Bristol Myers Squibb by 0.9% during the 4th quarter. Joel Isaacson & Co. LLC now owns 32,035 shares of the biopharmaceutical company's stock worth $1,728,000 after purchasing an additional 299 shares during the period. Archer Investment Corp increased its position in shares of Bristol Myers Squibb by 1.2% during the 4th quarter. Archer Investment Corp now owns 24,318 shares of the biopharmaceutical company's stock worth $1,312,000 after purchasing an additional 300 shares during the last quarter. SOL Capital Management CO increased its position in shares of Bristol Myers Squibb by 16.2% during the 4th quarter. SOL Capital Management CO now owns 10,768 shares of the biopharmaceutical company's stock worth $581,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Westhampton Capital LLC raised its holdings in Bristol Myers Squibb by 2.4% in the 4th quarter. Westhampton Capital LLC now owns 25,422 shares of the biopharmaceutical company's stock valued at $1,371,000 after buying an additional 605 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 0.8%

Shares of BMY opened at $58.26 on Wednesday. The company's 50-day simple moving average is $59.59 and its 200-day simple moving average is $54.41. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The stock has a market capitalization of $118.94 billion, a PE ratio of 16.89, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.28 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb's dividend payout ratio is currently 73.04%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BMY shares. Cantor Fitzgerald increased their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 8th. Guggenheim restated a "buy" rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Wells Fargo & Company reaffirmed an "outperform" rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Scotiabank reiterated a "sector perform" rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, UBS Group reissued a "buy" rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $61.31.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.